Literature DB >> 14647908

[Hepatic encephalopathy].

P D Schellinger1, M K Hartmann, Ch Klingmann, H M Meinck.   

Abstract

Hepatic encephalopathy (HE) is a neuropsychiatric complication of acute and chronic liver disease. Its etiology and pathogenesis are thought to be a complex, metabolically induced, and therefore potentially reversible disturbance in brain functions. The diagnosis is based on demonstrating both a disorder of the central nervous system and a concomitant liver disease as well as the exclusion of any neurological or psychiatric disorder of other etiology. The diagnosis of HE is clinical and displays a wide spectrum of neuropsychiatric symptoms in different degrees of severity. Ancillary diagnostic workup includes laboratory tests, neuroimaging, and neurophysiological exams such as electroencephalography and evoked potentials. The therapy of HE mainly consists of treatment and avoidance of any precipitating conditions such as high protein intake, infections, and gastrointestinal bleeding. Other therapeutic approaches modulate metabolic processes such as ammonium synthesis and excretion, formation of neurotransmitters, and as a last resort liver transplantation. The prognosis depends ultimately on the course of the liver disease.

Entities:  

Mesh:

Year:  2003        PMID: 14647908     DOI: 10.1007/s00115-003-1579-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  49 in total

Review 1.  [Hepatic encephalopathy].

Authors:  P Ferenci
Journal:  Dtsch Med Wochenschr       Date:  2001-06-01       Impact factor: 0.628

Review 2.  TIPS and hepatic encephalopathy.

Authors:  G Pomier-Layrargues
Journal:  Semin Liver Dis       Date:  1996-08       Impact factor: 6.115

3.  Synergism between ammonia and fatty acids in the production of coma: implications for hepatic coma.

Authors:  F J Zieve; L Zieve; W M Doizaki; R B Gilsdorf
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

4.  Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma.

Authors:  L Zieve; W M Doizaki; J Zieve
Journal:  J Lab Clin Med       Date:  1974-01

5.  Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy.

Authors:  A S Basile; S H Gammal; K D Mullen; E A Jones; P Skolnick
Journal:  J Neurosci       Date:  1988-07       Impact factor: 6.167

6.  Increased manganese concentrations in pallidum of cirrhotic patients.

Authors:  G Pomier-Layrargues; L Spahr; R F Butterworth
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

7.  Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.

Authors:  P Amodio; F Del Piccolo; P Marchetti; P Angeli; R Iemmolo; L Caregaro; C Merkel; G Gerunda; A Gatta
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

8.  Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.

Authors:  E Strauss; R Tramote; E P Silva; W R Caly; N Z Honain; R A Maffei; M F de Sá
Journal:  Hepatogastroenterology       Date:  1992-12

9.  Osmotic demyelination syndrome following correction of hyponatremia.

Authors:  R H Sterns; J E Riggs; S S Schochet
Journal:  N Engl J Med       Date:  1986-06-12       Impact factor: 91.245

10.  Manganese and chronic hepatic encephalopathy.

Authors:  D Krieger; S Krieger; O Jansen; P Gass; L Theilmann; H Lichtnecker
Journal:  Lancet       Date:  1995-07-29       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.